UroMems Raises $60M Strategic Investment Led By Ajax Health Fund I

As part of the deal, David Beylik and Dr. Jeremy Durack from Ajax Health have joined the company’s board of directors.

The funding will support large-scale pivotal clinical trials of UroMems’ UroActive® implant system across 21 centers in the United States and France, helping advance regulatory approvals in multiple markets.

Founded by CEO Hamid Lamraoui, UroMems has developed UroActive®, the first automated electronic artificial urinary sphincter (AUS) powered by an embedded smart bionic platform.

The device uses a MyoElectroMechanical System (MEMS) that adapts in real time to a patient’s activity data, eliminating the need for manual control and improving usability over traditional devices.

Read Also - UK Envoke Raises £1.6M To Advance Virtual Training Software For Medical Labs

The company holds a portfolio of more than 200 granted patents and is actively enrolling patients in its SOPHIA clinical trials to evaluate safety and performance.

This round builds on a $47 million Series C raised in June 2024, and further strengthens progress toward regulatory submissions in the U.S. and Europe.

"We're excited to fund this pivotal round for UroMems and apply our approach of partnering with potential industry leaders to help build and scale innovative medtech organizations," said David Beylik, partner at Ajax Health. "Combining our industry experience and capital with the UroMems team, we believe that the UroActive smart implant has the potential to become the standard of care for SUI treatment."

"Ajax Health Fund I's support strengthens our position as we approach the pivotal points of FDA PMA submission and commercialization, and we're grateful for their investment, partnership and confidence in UroActive," said Hamid Lamraoui, co-founder and chief executive officer of UroMems. "I believe UroActive will be a game-changer in treating patients suffering from SUI, and we are now one step closer to achieving our shared vision of delivering on the significant unmet need for patients and physicians desperately seeking a better SUI treatment option."

About UroMems

UroMems founded in 2011 and based in Eybens, France is a biotechnology research company developing advanced implantable medical technologies. The company focuses on innovative mechatronic and smart implant solutions aimed at treating stress urinary incontinence and improving patient outcomes through next-generation medical device engineering and research-driven healthcare innovation.